HER-2

ERBB2

A gene on chromosome 17q11.2-q12 that encodes a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. ERBB2 has no ligand-binding domain and thus cannot bind growth factors; it does, however, bind to other ligand-bound EGF receptor family members, forming a heterodimer, stabilising ligand binding and enhancing kinase-mediated activation of downstream signalling pathways (e.g., those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase).

Molecular pathology
ERBB2 amplification and overexpression commonly occurs in breast and ovarian cancers.

HER-2

c-erbB-2, HER-2/neu Oncology An erbB family oncogene related to epidermal growth factor; HER-2 overexpression, espceically breast CA, and stomach CAs, which have a ↓ survival and ↓ time to relapse. See Breast cancer.
References in periodicals archive ?
A FISH test for HER-2 / neu recently became commercially available from Vysis Inc.
Only a few women in Santa Clarita with the HER-2 gene qualified to participate in the study, he said.
0 million in grants from the DOD in the development of its live Listeria vaccines directed against HER-2 for breast cancer and HMW-MAA, an antiangiogenic vaccine.
9 December 2011 - Generex Biotechnology Corp (PINK:GNBT) unveiled on Thursday positive data from its Phase II clinical trial of a new Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37) in HER-2 expressing breast cancer patients.
The HER-2 protein, which is also known as c-erbB-2 or neu, is a member of subclass 1 of the superfamily of receptor tyrosine kinases.
Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), today announced the publication of a paper entitled "Treatment of Mammary Carcinomas in HER-2 Transgenic Mice through Combination of Genetic Vaccine and an Agonist of Toll-like Receptor 9" in Clinical Cancer Research (2009, 15, 1575-84) co-authored by scientists from Idera and Merck & Co.
These molecules are able to bind to two validated tumour targets: HER-2, which is present on aggressive breast tumours, and PDGFR-beta, which plays a significant role in angiogenesis associated with solid tumour growth and development.
It is used to treat patients with a gene mutation that results in too much of a protein known as HER-2, which fuels the progression of the disease.
The HER-2 gene (HER-2/neu or c-erbB-2) encodes an 185-kDa transmembrane glycoprotein that is a member of the type I family of growth factor receptors.
Abbott will provide ANGLE with its proprietary PathVysion HER-2 DNA FISH Probe kits for its ANG-002 US Food & Drug Administration (FDA) study for FISH (fluorescence in situ hybridisation) analysis of circulating tumour cells (CTCs) in the form of a research grant.
HER-2 affects 25per cent of women and has a poor prognosis.